Chemicals
Showing 38401–38550 of 41137 results
-
Topiramate is a sugar sulfamate with anticonvulsant activity.{18290} It inhibits carbonic anhydrase in intact human erythrocytes (Ki = ~200 μM), as well as blocks sodium and calcium channels and kainate-induced currents in vitro.{18290,32575,48075} It also increases GABAA receptor-mediated chloride ion flux.{48075} Topiramate inhibits hind-limb tonic-extensor seizures in the maximal electroshock seizure test in mice (ED50 = 39 mg/kg, p.o.).{18290} Formulations containing topiramate have been used in the treatment of epilepsy and prophylaxis of migraine headaches.
Brand:CaymanSKU:- Topiramate is a sugar sulfamate with anticonvulsant activity.{18290} It inhibits carbonic anhydrase in intact human erythrocytes (Ki = ~200 μM), as well as blocks sodium and calcium channels and kainate-induced currents in vitro.{18290,32575,48075} It also increases GABAA receptor-mediated chloride ion flux.{48075} Topiramate inhibits hind-limb tonic-extensor seizures in the maximal electroshock seizure test in mice (ED50 = 39 mg/kg, p.o.).{18290} Formulations containing topiramate have been used in the treatment of epilepsy and prophylaxis of migraine headaches.
Brand:CaymanSKU:- Topiramate is a sugar sulfamate with anticonvulsant activity.{18290} It inhibits carbonic anhydrase in intact human erythrocytes (Ki = ~200 μM), as well as blocks sodium and calcium channels and kainate-induced currents in vitro.{18290,32575,48075} It also increases GABAA receptor-mediated chloride ion flux.{48075} Topiramate inhibits hind-limb tonic-extensor seizures in the maximal electroshock seizure test in mice (ED50 = 39 mg/kg, p.o.).{18290} Formulations containing topiramate have been used in the treatment of epilepsy and prophylaxis of migraine headaches.
Brand:CaymanSKU:-
Topiramate-d12 is intended for use as an internal standard for the quantification of topiramate (Item No. 13623) by GC- or LC-MS. Topiramate is a sugar sulfamate with anticonvulsant activity.{18290} It inhibits carbonic anhydrase in intact human erythrocytes (Ki = ~200 μM), as well as blocks sodium and calcium channels and kainate-induced currents in vitro.{18290,32575,48075} It also increases GABAA receptor-mediated chloride ion flux.{48075} Topiramate inhibits hind-limb tonic-extensor seizures in the maximal electroshock seizure test in mice (ED50 = 39 mg/kg, p.o.).{18290} Formulations containing topiramate have been used in the treatment of epilepsy and prophylaxis of migraine headaches.
Brand:CaymanSKU:26443 - 1 mgAvailable on backorder
Topiramate-d12 is intended for use as an internal standard for the quantification of topiramate (Item No. 13623) by GC- or LC-MS. Topiramate is a sugar sulfamate with anticonvulsant activity.{18290} It inhibits carbonic anhydrase in intact human erythrocytes (Ki = ~200 μM), as well as blocks sodium and calcium channels and kainate-induced currents in vitro.{18290,32575,48075} It also increases GABAA receptor-mediated chloride ion flux.{48075} Topiramate inhibits hind-limb tonic-extensor seizures in the maximal electroshock seizure test in mice (ED50 = 39 mg/kg, p.o.).{18290} Formulations containing topiramate have been used in the treatment of epilepsy and prophylaxis of migraine headaches.
Brand:CaymanSKU:26443 - 10 mgAvailable on backorder
Topiramate-d12 is intended for use as an internal standard for the quantification of topiramate (Item No. 13623) by GC- or LC-MS. Topiramate is a sugar sulfamate with anticonvulsant activity.{18290} It inhibits carbonic anhydrase in intact human erythrocytes (Ki = ~200 μM), as well as blocks sodium and calcium channels and kainate-induced currents in vitro.{18290,32575,48075} It also increases GABAA receptor-mediated chloride ion flux.{48075} Topiramate inhibits hind-limb tonic-extensor seizures in the maximal electroshock seizure test in mice (ED50 = 39 mg/kg, p.o.).{18290} Formulations containing topiramate have been used in the treatment of epilepsy and prophylaxis of migraine headaches.
Brand:CaymanSKU:26443 - 5 mgAvailable on backorder
Topiramate-d12 is intended for use as an internal standard for the quantification of topiramate (Item No. 13623) by GC- or LC-MS. Topiramate is a sugar sulfamate with anticonvulsant activity.{18290} It inhibits carbonic anhydrase in intact human erythrocytes (Ki = ~200 μM), as well as blocks sodium and calcium channels and kainate-induced currents in vitro.{18290,32575,48075} It also increases GABAA receptor-mediated chloride ion flux.{48075} Topiramate inhibits hind-limb tonic-extensor seizures in the maximal electroshock seizure test in mice (ED50 = 39 mg/kg, p.o.).{18290} Formulations containing topiramate have been used in the treatment of epilepsy and prophylaxis of migraine headaches.
Brand:CaymanSKU:26443 - 500 µgAvailable on backorder
Topiroxostat is an inhibitor of xanthine oxidoreductase (IC50 = 5.3 nM), an enzyme that converts xanthine to urate.{33356} Formulations containing topiroxostat are effective in vivo, lowering urate levels in the serum of patients with hyperuricemia.{33354} In rats, but not primates, topiroxostat treatment results in the formation of xanthine crystals, resulting in nephritis.{33357,33358} Topiroxostat also inhibits ATP-binding cassette transporter G2 (ABCG2; IC50 = 0.18 µM), a high-capacity urate transporter that functions in both renal and extrarenal urate secretion.{33355}
Brand:CaymanSKU:21267 -Out of stock
Topiroxostat is an inhibitor of xanthine oxidoreductase (IC50 = 5.3 nM), an enzyme that converts xanthine to urate.{33356} Formulations containing topiroxostat are effective in vivo, lowering urate levels in the serum of patients with hyperuricemia.{33354} In rats, but not primates, topiroxostat treatment results in the formation of xanthine crystals, resulting in nephritis.{33357,33358} Topiroxostat also inhibits ATP-binding cassette transporter G2 (ABCG2; IC50 = 0.18 µM), a high-capacity urate transporter that functions in both renal and extrarenal urate secretion.{33355}
Brand:CaymanSKU:21267 -Out of stock
Topiroxostat is an inhibitor of xanthine oxidoreductase (IC50 = 5.3 nM), an enzyme that converts xanthine to urate.{33356} Formulations containing topiroxostat are effective in vivo, lowering urate levels in the serum of patients with hyperuricemia.{33354} In rats, but not primates, topiroxostat treatment results in the formation of xanthine crystals, resulting in nephritis.{33357,33358} Topiroxostat also inhibits ATP-binding cassette transporter G2 (ABCG2; IC50 = 0.18 µM), a high-capacity urate transporter that functions in both renal and extrarenal urate secretion.{33355}
Brand:CaymanSKU:21267 -Out of stock
Topiroxostat is an inhibitor of xanthine oxidoreductase (IC50 = 5.3 nM), an enzyme that converts xanthine to urate.{33356} Formulations containing topiroxostat are effective in vivo, lowering urate levels in the serum of patients with hyperuricemia.{33354} In rats, but not primates, topiroxostat treatment results in the formation of xanthine crystals, resulting in nephritis.{33357,33358} Topiroxostat also inhibits ATP-binding cassette transporter G2 (ABCG2; IC50 = 0.18 µM), a high-capacity urate transporter that functions in both renal and extrarenal urate secretion.{33355}
Brand:CaymanSKU:21267 -Out of stock
Topotecan is an inhibitor of DNA topoisomerase I and a derivative of the DNA topoisomerase I inhibitor camptothecin (Item No. 11694).{21114,21115,22689} Topotecan inhibits DNA topoisomerase I in human MCF-7 breast and DU-145 prostate cancer cells with IC50 values of 13 and 2 nM, respectively, in a cell-based luciferase reporter assay.{42991} Topotecan induces cytotoxicity and DNA damage in HT-29 human colon adenocarcinoma cells with (IC50s = 33 and 280 nM, respectively.{21114} Formulations containing topotecan have been used in the treatment of small-cell lung cancer.
Brand:CaymanSKU:- Topotecan is an inhibitor of DNA topoisomerase I and a derivative of the DNA topoisomerase I inhibitor camptothecin (Item No. 11694).{21114,21115,22689} Topotecan inhibits DNA topoisomerase I in human MCF-7 breast and DU-145 prostate cancer cells with IC50 values of 13 and 2 nM, respectively, in a cell-based luciferase reporter assay.{42991} Topotecan induces cytotoxicity and DNA damage in HT-29 human colon adenocarcinoma cells with (IC50s = 33 and 280 nM, respectively.{21114} Formulations containing topotecan have been used in the treatment of small-cell lung cancer.
Brand:CaymanSKU:- Topotecan is an inhibitor of DNA topoisomerase I and a derivative of the DNA topoisomerase I inhibitor camptothecin (Item No. 11694).{21114,21115,22689} Topotecan inhibits DNA topoisomerase I in human MCF-7 breast and DU-145 prostate cancer cells with IC50 values of 13 and 2 nM, respectively, in a cell-based luciferase reporter assay.{42991} Topotecan induces cytotoxicity and DNA damage in HT-29 human colon adenocarcinoma cells with (IC50s = 33 and 280 nM, respectively.{21114} Formulations containing topotecan have been used in the treatment of small-cell lung cancer.
Brand:CaymanSKU:- Topotecan is an inhibitor of DNA topoisomerase I and a derivative of the DNA topoisomerase I inhibitor camptothecin (Item No. 11694).{21114,21115,22689} Topotecan inhibits DNA topoisomerase I in human MCF-7 breast and DU-145 prostate cancer cells with IC50 values of 13 and 2 nM, respectively, in a cell-based luciferase reporter assay.{42991} Topotecan induces cytotoxicity and DNA damage in HT-29 human colon adenocarcinoma cells with (IC50s = 33 and 280 nM, respectively.{21114} Formulations containing topotecan have been used in the treatment of small-cell lung cancer.
Brand:CaymanSKU:-
Topotecan-d6 is intended for use as an internal standard for the quantification of topotecan (Item No. 14129) by GC- or LC-MS. Topotecan is an inhibitor of DNA topoisomerase I and a derivative of the DNA topoisomerase I inhibitor camptothecin (Item No. 11694).{21114,21115,22689} Topotecan inhibits DNA topoisomerase I in human MCF-7 breast and DU145 prostate cancer cells with IC50 values of 13 and 2 nM, respectively, in a cell-based luciferase reporter assay.{42991} Topotecan induces cytotoxicity and DNA damage in HT-29 human colon adenocarcinoma cells (IC50s = 33 and 280 nM, respectively).{21114} Formulations containing topotecan have been used in the treatment of small-cell lung cancer.
Brand:CaymanSKU:29082 - 1 mgAvailable on backorder
Topotecan-d6 is intended for use as an internal standard for the quantification of topotecan (Item No. 14129) by GC- or LC-MS. Topotecan is an inhibitor of DNA topoisomerase I and a derivative of the DNA topoisomerase I inhibitor camptothecin (Item No. 11694).{21114,21115,22689} Topotecan inhibits DNA topoisomerase I in human MCF-7 breast and DU145 prostate cancer cells with IC50 values of 13 and 2 nM, respectively, in a cell-based luciferase reporter assay.{42991} Topotecan induces cytotoxicity and DNA damage in HT-29 human colon adenocarcinoma cells (IC50s = 33 and 280 nM, respectively).{21114} Formulations containing topotecan have been used in the treatment of small-cell lung cancer.
Brand:CaymanSKU:29082 - 500 µgAvailable on backorder
Torasemide (Item No. 21312) is an analytical reference standard categorized as a diuretic.{26628,33155,33139} Diuretics, including torasemide, have been abused as performance-enhancing drugs and masking agents in doping in sports.{33139} This product is intended for research and forensic applications.
Brand:CaymanSKU:21312 -Out of stock
Torasemide (Item No. 21312) is an analytical reference standard categorized as a diuretic.{26628,33155,33139} Diuretics, including torasemide, have been abused as performance-enhancing drugs and masking agents in doping in sports.{33139} This product is intended for research and forensic applications.
Brand:CaymanSKU:21312 -Out of stock
Torasemide (Item No. 21312) is an analytical reference standard categorized as a diuretic.{26628,33155,33139} Diuretics, including torasemide, have been abused as performance-enhancing drugs and masking agents in doping in sports.{33139} This product is intended for research and forensic applications.
Brand:CaymanSKU:21312 -Out of stock
Torasemide-d7 is intended for use as an internal standard for the quantification of torasemide by GC- or LC-MS. Torasemide is a loop diuretic.{33155} In vivo, torasemide (6 mg/kg) increases fractional potassium, sodium, and chloride excretion and increases urine flow in rats. Formulations containing torsemide have been used to treat edema associated with congestive heart failure, kidney disease, and liver disease, as well as high blood pressure.
Brand:CaymanSKU:26790 - 1 mgAvailable on backorder
Torasemide-d7 is intended for use as an internal standard for the quantification of torasemide by GC- or LC-MS. Torasemide is a loop diuretic.{33155} In vivo, torasemide (6 mg/kg) increases fractional potassium, sodium, and chloride excretion and increases urine flow in rats. Formulations containing torsemide have been used to treat edema associated with congestive heart failure, kidney disease, and liver disease, as well as high blood pressure.
Brand:CaymanSKU:26790 - 5 mgAvailable on backorder
Torasemide-d7 is intended for use as an internal standard for the quantification of torasemide by GC- or LC-MS. Torasemide is a loop diuretic.{33155} In vivo, torasemide (6 mg/kg) increases fractional potassium, sodium, and chloride excretion and increases urine flow in rats. Formulations containing torsemide have been used to treat edema associated with congestive heart failure, kidney disease, and liver disease, as well as high blood pressure.
Brand:CaymanSKU:26790 - 500 µgAvailable on backorder
Cholesteryl ester transfer protein (CETP) catalyzes the exchange of cholesteryl esters from high-density lipoprotein (HDL) cholesterol to apolipoprotein B-containing lipoproteins, including very low-density lipoprotein (VLDL) and LDL.{22539} Torcetrapib is an inhibitor of CETP activity (IC50 = 50 nM) that raises HDL cholesterol and reduces LDL cholesterol levels by forming a nonproductive complex between CETP and HDL.{14626} Although torcetrapib produced consistent antiatherogenic effects in rabbits, clinical trials of torcetrapib were terminated early due to deleterious hypertensive effects.{22539, 22538} PDGFR, HGFR (c-Met), IL-2 receptor, and ErbB1- tyrosine kinase have subsequently been identified as direct off-targets of this compound.{22540}
Brand:CaymanSKU:- Cholesteryl ester transfer protein (CETP) catalyzes the exchange of cholesteryl esters from high-density lipoprotein (HDL) cholesterol to apolipoprotein B-containing lipoproteins, including very low-density lipoprotein (VLDL) and LDL.{22539} Torcetrapib is an inhibitor of CETP activity (IC50 = 50 nM) that raises HDL cholesterol and reduces LDL cholesterol levels by forming a nonproductive complex between CETP and HDL.{14626} Although torcetrapib produced consistent antiatherogenic effects in rabbits, clinical trials of torcetrapib were terminated early due to deleterious hypertensive effects.{22539, 22538} PDGFR, HGFR (c-Met), IL-2 receptor, and ErbB1- tyrosine kinase have subsequently been identified as direct off-targets of this compound.{22540}
Brand:CaymanSKU:- Cholesteryl ester transfer protein (CETP) catalyzes the exchange of cholesteryl esters from high-density lipoprotein (HDL) cholesterol to apolipoprotein B-containing lipoproteins, including very low-density lipoprotein (VLDL) and LDL.{22539} Torcetrapib is an inhibitor of CETP activity (IC50 = 50 nM) that raises HDL cholesterol and reduces LDL cholesterol levels by forming a nonproductive complex between CETP and HDL.{14626} Although torcetrapib produced consistent antiatherogenic effects in rabbits, clinical trials of torcetrapib were terminated early due to deleterious hypertensive effects.{22539, 22538} PDGFR, HGFR (c-Met), IL-2 receptor, and ErbB1- tyrosine kinase have subsequently been identified as direct off-targets of this compound.{22540}
Brand:CaymanSKU:-
Toremifene (citrate) is an orally bioavailable selective estrogen receptor modulator (SERM) that evokes tissue-dependent effects similar to that of tamoxifen (Item No. 13258).{23588} It has been shown to block estrogen-stimulated growth of MCF-7 breast cancer cells grown in tissue culture, to inhibit ovariectomy-induced bone loss in rats, and to stimulate endometrial growth similar to that of tamoxifen.{23588}
Brand:CaymanSKU:20854 -Out of stock
Toremifene (citrate) is an orally bioavailable selective estrogen receptor modulator (SERM) that evokes tissue-dependent effects similar to that of tamoxifen (Item No. 13258).{23588} It has been shown to block estrogen-stimulated growth of MCF-7 breast cancer cells grown in tissue culture, to inhibit ovariectomy-induced bone loss in rats, and to stimulate endometrial growth similar to that of tamoxifen.{23588}
Brand:CaymanSKU:20854 -Out of stock
Toremifene (citrate) is an orally bioavailable selective estrogen receptor modulator (SERM) that evokes tissue-dependent effects similar to that of tamoxifen (Item No. 13258).{23588} It has been shown to block estrogen-stimulated growth of MCF-7 breast cancer cells grown in tissue culture, to inhibit ovariectomy-induced bone loss in rats, and to stimulate endometrial growth similar to that of tamoxifen.{23588}
Brand:CaymanSKU:20854 -Out of stock
Toremifene (citrate) is an orally bioavailable selective estrogen receptor modulator (SERM) that evokes tissue-dependent effects similar to that of tamoxifen (Item No. 13258).{23588} It has been shown to block estrogen-stimulated growth of MCF-7 breast cancer cells grown in tissue culture, to inhibit ovariectomy-induced bone loss in rats, and to stimulate endometrial growth similar to that of tamoxifen.{23588}
Brand:CaymanSKU:20854 -Out of stock
Torin 1 is a potent and selective inhibitor of mTOR (IC50 = 2 and 10 nM for mTORC1 and mTORC2, respectively).{19694,19693} It shows over 100-fold selectivity for mTOR over PI3Kα and other PI3K-like kinases, including ATM, DNA-PK, and hVps34, as well as 450 other protein kinases.{19694,19693} Torin 1, is efficacious at a dose of 20 mg/kg in inhibiting downstream effectors of mTOR in mice.{19693}
Brand:CaymanSKU:10997 - 10 mgAvailable on backorder
Torin 1 is a potent and selective inhibitor of mTOR (IC50 = 2 and 10 nM for mTORC1 and mTORC2, respectively).{19694,19693} It shows over 100-fold selectivity for mTOR over PI3Kα and other PI3K-like kinases, including ATM, DNA-PK, and hVps34, as well as 450 other protein kinases.{19694,19693} Torin 1, is efficacious at a dose of 20 mg/kg in inhibiting downstream effectors of mTOR in mice.{19693}
Brand:CaymanSKU:10997 - 25 mgAvailable on backorder
Torin 1 is a potent and selective inhibitor of mTOR (IC50 = 2 and 10 nM for mTORC1 and mTORC2, respectively).{19694,19693} It shows over 100-fold selectivity for mTOR over PI3Kα and other PI3K-like kinases, including ATM, DNA-PK, and hVps34, as well as 450 other protein kinases.{19694,19693} Torin 1, is efficacious at a dose of 20 mg/kg in inhibiting downstream effectors of mTOR in mice.{19693}
Brand:CaymanSKU:10997 - 50 mgAvailable on backorder
Torin 2 is a potent and selective inhibitor of cellular mTOR activity (EC50 = 0.3 nM).{22455} It shows more than 800-fold selectivity for mTOR over PI3K (EC50 = 200 nM) and greater than 100-fold binding selectivity relative to 440 other protein kinases.{22455} Torin 2 has significantly improved bioavailability (54%), metabolic stability, and plasma exposure compared to torin 1 (Item No. 10997).{22455,19694}
Brand:CaymanSKU:- Torin 2 is a potent and selective inhibitor of cellular mTOR activity (EC50 = 0.3 nM).{22455} It shows more than 800-fold selectivity for mTOR over PI3K (EC50 = 200 nM) and greater than 100-fold binding selectivity relative to 440 other protein kinases.{22455} Torin 2 has significantly improved bioavailability (54%), metabolic stability, and plasma exposure compared to torin 1 (Item No. 10997).{22455,19694}
Brand:CaymanSKU:- Torin 2 is a potent and selective inhibitor of cellular mTOR activity (EC50 = 0.3 nM).{22455} It shows more than 800-fold selectivity for mTOR over PI3K (EC50 = 200 nM) and greater than 100-fold binding selectivity relative to 440 other protein kinases.{22455} Torin 2 has significantly improved bioavailability (54%), metabolic stability, and plasma exposure compared to torin 1 (Item No. 10997).{22455,19694}
Brand:CaymanSKU:-
Tosedostat is an inhibitor of aminopeptidases (IC50s = 100, 150, and 220 nM for LAP, PUSA, and aminopeptidase N, respectively).{37251} It inhibits proliferation of human leukemia cell lines in vitro irrespective of p53, PTEN, or K-RAS mutational status (IC50s = 10-770 nM). Tosedostat induces up-regulation of genes in amino acid transport and metabolic pathways and inhibits phosphorylation of mammalian target of rapamycin (mTOR) substrates in HL-60 cells, markers of amino acid depletion. In vivo, tosedostat (100 mg/kg) reduces total tumor burden and the number of spontaneous metastases in a mouse MDA-MB-435 xenograft model. Formulations containing tosedostat are under clinical investigation for the treatment of myeloid leukemia.
Brand:CaymanSKU:23395 - 1 mgAvailable on backorder
Tosedostat is an inhibitor of aminopeptidases (IC50s = 100, 150, and 220 nM for LAP, PUSA, and aminopeptidase N, respectively).{37251} It inhibits proliferation of human leukemia cell lines in vitro irrespective of p53, PTEN, or K-RAS mutational status (IC50s = 10-770 nM). Tosedostat induces up-regulation of genes in amino acid transport and metabolic pathways and inhibits phosphorylation of mammalian target of rapamycin (mTOR) substrates in HL-60 cells, markers of amino acid depletion. In vivo, tosedostat (100 mg/kg) reduces total tumor burden and the number of spontaneous metastases in a mouse MDA-MB-435 xenograft model. Formulations containing tosedostat are under clinical investigation for the treatment of myeloid leukemia.
Brand:CaymanSKU:23395 - 5 mgAvailable on backorder
Tosufloxacin is a fluoroquinolone antibiotic. It has activity against diverse aerobic and anaerobic bacteria in vitro.{33732,33733} Tosufloxacin is also effective against bacterial persisters, showing significant activity against S. aureus and uropathogenic E. coli persisters.{33734,33735} As with many other quinolones, tosufloxacin use can be associated with significant side effects.{33736}
Brand:CaymanSKU:21427 -Out of stock
Tosufloxacin is a fluoroquinolone antibiotic. It has activity against diverse aerobic and anaerobic bacteria in vitro.{33732,33733} Tosufloxacin is also effective against bacterial persisters, showing significant activity against S. aureus and uropathogenic E. coli persisters.{33734,33735} As with many other quinolones, tosufloxacin use can be associated with significant side effects.{33736}
Brand:CaymanSKU:21427 -Out of stock
Tosufloxacin is a fluoroquinolone antibiotic. It has activity against diverse aerobic and anaerobic bacteria in vitro.{33732,33733} Tosufloxacin is also effective against bacterial persisters, showing significant activity against S. aureus and uropathogenic E. coli persisters.{33734,33735} As with many other quinolones, tosufloxacin use can be associated with significant side effects.{33736}
Brand:CaymanSKU:21427 -Out of stock
Tosufloxacin is a fluoroquinolone antibiotic. It has activity against diverse aerobic and anaerobic bacteria in vitro.{33732,33733} Tosufloxacin is also effective against bacterial persisters, showing significant activity against S. aureus and uropathogenic E. coli persisters.{33734,33735} As with many other quinolones, tosufloxacin use can be associated with significant side effects.{33736}
Brand:CaymanSKU:21427 -Out of stock
Tosyl phenylalanyl chloromethyl ketone (TPCK) is an irreversible inhibitor of chymotrypsin-like proteases that has been shown to affect cell proliferation, apoptosis, and tumorigenesis.{33079} It can disrupt PDK1 signaling to the AGC kinases, Akt, S6K1, and RSK, as well as MSK1 and MSK2.{33078} TPCK also inhibits superoxide production and suppresses neutrophil respiratory burst.{33080}
Brand:CaymanSKU:20166 -Available on backorder
Tosyl phenylalanyl chloromethyl ketone (TPCK) is an irreversible inhibitor of chymotrypsin-like proteases that has been shown to affect cell proliferation, apoptosis, and tumorigenesis.{33079} It can disrupt PDK1 signaling to the AGC kinases, Akt, S6K1, and RSK, as well as MSK1 and MSK2.{33078} TPCK also inhibits superoxide production and suppresses neutrophil respiratory burst.{33080}
Brand:CaymanSKU:20166 -Available on backorder
Tosyl phenylalanyl chloromethyl ketone (TPCK) is an irreversible inhibitor of chymotrypsin-like proteases that has been shown to affect cell proliferation, apoptosis, and tumorigenesis.{33079} It can disrupt PDK1 signaling to the AGC kinases, Akt, S6K1, and RSK, as well as MSK1 and MSK2.{33078} TPCK also inhibits superoxide production and suppresses neutrophil respiratory burst.{33080}
Brand:CaymanSKU:20166 -Available on backorder
Tosyl phenylalanyl chloromethyl ketone (TPCK) is an irreversible inhibitor of chymotrypsin-like proteases that has been shown to affect cell proliferation, apoptosis, and tumorigenesis.{33079} It can disrupt PDK1 signaling to the AGC kinases, Akt, S6K1, and RSK, as well as MSK1 and MSK2.{33078} TPCK also inhibits superoxide production and suppresses neutrophil respiratory burst.{33080}
Brand:CaymanSKU:20166 -Available on backorder
Tosyllysine chloromethylketone (TLCK) is an active site-directed agent that inhibits serine proteinases with trypsin-like activity. TLCK may also act non-selectively with thiol groups and thereby inhibit cysteine proteinases and other enzymes.{13825} To prevent proteolytic degradation, TLCK may be used in protein purification protocols.{16785} TLCK selectively inactiviates clostripain obtained from C. histolyticum.{16786}
Brand:CaymanSKU:- Tosyllysine chloromethylketone (TLCK) is an active site-directed agent that inhibits serine proteinases with trypsin-like activity. TLCK may also act non-selectively with thiol groups and thereby inhibit cysteine proteinases and other enzymes.{13825} To prevent proteolytic degradation, TLCK may be used in protein purification protocols.{16785} TLCK selectively inactiviates clostripain obtained from C. histolyticum.{16786}
Brand:CaymanSKU:- Tosyllysine chloromethylketone (TLCK) is an active site-directed agent that inhibits serine proteinases with trypsin-like activity. TLCK may also act non-selectively with thiol groups and thereby inhibit cysteine proteinases and other enzymes.{13825} To prevent proteolytic degradation, TLCK may be used in protein purification protocols.{16785} TLCK selectively inactiviates clostripain obtained from C. histolyticum.{16786}
Brand:CaymanSKU:-
Enzymatic method the determination of Cholesterol in serum.
Brand:FUJIFILM Medical Systems USASKU:999-02601Available on backorder
Cyclic Enzymatic method for the determination of total ketone bodies in serum or plasma.
Brand:FUJIFILM Medical Systems USASKU:415-73301Available on backorder
Cyclic Enzymatic method for the determination of total ketone bodies in serum or plasma.
Brand:FUJIFILM Medical Systems USASKU:411-73401Available on backorder
Totarol is a diterpene originally isolated from P. totara that has diverse biological activities, including antibacterial, antioxidant, and neuroprotective properties.{43637} It is active against Gram-positive bacteria, including P. acnes, S. mutans, B. subtilis, and B. ammoniagenes (MICs = 0.39, 0.78, 1.56, and 0.78 µg/ml, respectively), as well as penicillin-resistant and -susceptible strains of S. aureus (MICs = 0.78 and 1.56 µg/ml, respectively).{43638} It inhibits mitochondrial respiration in P. aeruginosa, inhibiting NADH-cytochrome c, NADH-DPIP, and NADH-coenzyme Q reductases but not cytochrome c oxidase.{43639} Totarol inhibits Fe(III)-ADP/NADPH-induced lipid oxidation in rat liver microsomes and mitochondria (IC50s = 4.79 and 0.47 µM, respectively) and autooxidation of linoleic acid (Item No. 90150) with an IC50 value of 9.8 µM.{43640} In rat primary cerebellar granule cells, totarol increases Akt and GSK-3β phosphorylation when used at a concentration of 5 µM and prevents neuronal death induced by glutamate or oxygen and glucose deprivation.{43641} It also reduces infarct volume in a rat model of acute cerebral ischemic injury when administered at doses of 1 and 10 microgram/kg.
Brand:CaymanSKU:26412 - 10 mgAvailable on backorder
Totarol is a diterpene originally isolated from P. totara that has diverse biological activities, including antibacterial, antioxidant, and neuroprotective properties.{43637} It is active against Gram-positive bacteria, including P. acnes, S. mutans, B. subtilis, and B. ammoniagenes (MICs = 0.39, 0.78, 1.56, and 0.78 µg/ml, respectively), as well as penicillin-resistant and -susceptible strains of S. aureus (MICs = 0.78 and 1.56 µg/ml, respectively).{43638} It inhibits mitochondrial respiration in P. aeruginosa, inhibiting NADH-cytochrome c, NADH-DPIP, and NADH-coenzyme Q reductases but not cytochrome c oxidase.{43639} Totarol inhibits Fe(III)-ADP/NADPH-induced lipid oxidation in rat liver microsomes and mitochondria (IC50s = 4.79 and 0.47 µM, respectively) and autooxidation of linoleic acid (Item No. 90150) with an IC50 value of 9.8 µM.{43640} In rat primary cerebellar granule cells, totarol increases Akt and GSK-3β phosphorylation when used at a concentration of 5 µM and prevents neuronal death induced by glutamate or oxygen and glucose deprivation.{43641} It also reduces infarct volume in a rat model of acute cerebral ischemic injury when administered at doses of 1 and 10 microgram/kg.
Brand:CaymanSKU:26412 - 25 mgAvailable on backorder
Totarol is a diterpene originally isolated from P. totara that has diverse biological activities, including antibacterial, antioxidant, and neuroprotective properties.{43637} It is active against Gram-positive bacteria, including P. acnes, S. mutans, B. subtilis, and B. ammoniagenes (MICs = 0.39, 0.78, 1.56, and 0.78 µg/ml, respectively), as well as penicillin-resistant and -susceptible strains of S. aureus (MICs = 0.78 and 1.56 µg/ml, respectively).{43638} It inhibits mitochondrial respiration in P. aeruginosa, inhibiting NADH-cytochrome c, NADH-DPIP, and NADH-coenzyme Q reductases but not cytochrome c oxidase.{43639} Totarol inhibits Fe(III)-ADP/NADPH-induced lipid oxidation in rat liver microsomes and mitochondria (IC50s = 4.79 and 0.47 µM, respectively) and autooxidation of linoleic acid (Item No. 90150) with an IC50 value of 9.8 µM.{43640} In rat primary cerebellar granule cells, totarol increases Akt and GSK-3β phosphorylation when used at a concentration of 5 µM and prevents neuronal death induced by glutamate or oxygen and glucose deprivation.{43641} It also reduces infarct volume in a rat model of acute cerebral ischemic injury when administered at doses of 1 and 10 microgram/kg.
Brand:CaymanSKU:26412 - 50 mgAvailable on backorder
Tozadenant is an adenosine A2A receptor antagonist (Kis = 11.5 and 6 nM for the human and rhesus monkey receptors, respectively).{47787} It increases the distance traveled and reduces contralateral asymmetry in the open field test in a rat model of Parkinson’s disease induced by 6-OHDA (Item No. 25330) when administered at a dose of 30 mg/kg.{47788} Tozadenant (150 mg/kg) reverses locomotor deficits and restores novel object-stimulated locomotion in a marmoset model of MPTP-induced Parkinson’s disease.{47789}
Brand:CaymanSKU:28452 - 10 mgAvailable on backorder
Tozadenant is an adenosine A2A receptor antagonist (Kis = 11.5 and 6 nM for the human and rhesus monkey receptors, respectively).{47787} It increases the distance traveled and reduces contralateral asymmetry in the open field test in a rat model of Parkinson’s disease induced by 6-OHDA (Item No. 25330) when administered at a dose of 30 mg/kg.{47788} Tozadenant (150 mg/kg) reverses locomotor deficits and restores novel object-stimulated locomotion in a marmoset model of MPTP-induced Parkinson’s disease.{47789}
Brand:CaymanSKU:28452 - 100 mgAvailable on backorder
Tozadenant is an adenosine A2A receptor antagonist (Kis = 11.5 and 6 nM for the human and rhesus monkey receptors, respectively).{47787} It increases the distance traveled and reduces contralateral asymmetry in the open field test in a rat model of Parkinson’s disease induced by 6-OHDA (Item No. 25330) when administered at a dose of 30 mg/kg.{47788} Tozadenant (150 mg/kg) reverses locomotor deficits and restores novel object-stimulated locomotion in a marmoset model of MPTP-induced Parkinson’s disease.{47789}
Brand:CaymanSKU:28452 - 25 mgAvailable on backorder
Tozadenant is an adenosine A2A receptor antagonist (Kis = 11.5 and 6 nM for the human and rhesus monkey receptors, respectively).{47787} It increases the distance traveled and reduces contralateral asymmetry in the open field test in a rat model of Parkinson’s disease induced by 6-OHDA (Item No. 25330) when administered at a dose of 30 mg/kg.{47788} Tozadenant (150 mg/kg) reverses locomotor deficits and restores novel object-stimulated locomotion in a marmoset model of MPTP-induced Parkinson’s disease.{47789}
Brand:CaymanSKU:28452 - 50 mgAvailable on backorder
TP-064 is a potent inhibitor of protein arginine methyltransferase 4 (PRMT4; IC50 50 = 43 nM) in vitro. For more information on TP-064 please visit the Structural Genomics Consortium (SGC). The negative control, TP-064N, for TP-064 is also available exclusively through the SGC. You can submit a request to receive the negative control here.
Brand:CaymanSKU:20256 -Available on backorder
TP-064 is a potent inhibitor of protein arginine methyltransferase 4 (PRMT4; IC50 50 = 43 nM) in vitro. For more information on TP-064 please visit the Structural Genomics Consortium (SGC). The negative control, TP-064N, for TP-064 is also available exclusively through the SGC. You can submit a request to receive the negative control here.
Brand:CaymanSKU:20256 -Available on backorder
TP-064 is a potent inhibitor of protein arginine methyltransferase 4 (PRMT4; IC50 50 = 43 nM) in vitro. For more information on TP-064 please visit the Structural Genomics Consortium (SGC). The negative control, TP-064N, for TP-064 is also available exclusively through the SGC. You can submit a request to receive the negative control here.
Brand:CaymanSKU:20256 -Available on backorder
TP-064 is a potent inhibitor of protein arginine methyltransferase 4 (PRMT4; IC50 50 = 43 nM) in vitro. For more information on TP-064 please visit the Structural Genomics Consortium (SGC). The negative control, TP-064N, for TP-064 is also available exclusively through the SGC. You can submit a request to receive the negative control here.
Brand:CaymanSKU:20256 -Available on backorder
TP-0903 is an inhibitor of the receptor tyrosine kinase Axl (IC50 = 27 nM ).{53037} It exhibits greater than 50% inhibition of 11 kinases, including MER, TYRO3, JAK2, ALK, and Abl1, in a panel of 75 kinases at 200 nM, with IC50 values of 3 and 12.4 nM for Aurora A and B, respectively. TP-0903 decreases the phosphorylation of Akt and Axl in GAS6-stimulated, serum-starved PSN-1 pancreatic cancer cells (EC50s = 305 and 222 nM, respectively). It decreases cell viability (IC50 = 6 nM) and induces cell cycle arrest at the G2/M phase in PSN-1 cells when used at a concentration of 30 nM. TP-0903 also reduces the viability of colorectal cancer (CRC) cell lines with IC50 values ranging from 4.5 to 123 nM.{53038} It exhibits 69 and 44% tumor growth inhibition in an HCT116 mouse xenograft model and a K-Ras-mutant CRC patient-derived xenograft (PDX) mouse model, respectively, when administered at a dose of 40 mg/kg.
Brand:CaymanSKU:28757 - 1 mgAvailable on backorder
TP-0903 is an inhibitor of the receptor tyrosine kinase Axl (IC50 = 27 nM ).{53037} It exhibits greater than 50% inhibition of 11 kinases, including MER, TYRO3, JAK2, ALK, and Abl1, in a panel of 75 kinases at 200 nM, with IC50 values of 3 and 12.4 nM for Aurora A and B, respectively. TP-0903 decreases the phosphorylation of Akt and Axl in GAS6-stimulated, serum-starved PSN-1 pancreatic cancer cells (EC50s = 305 and 222 nM, respectively). It decreases cell viability (IC50 = 6 nM) and induces cell cycle arrest at the G2/M phase in PSN-1 cells when used at a concentration of 30 nM. TP-0903 also reduces the viability of colorectal cancer (CRC) cell lines with IC50 values ranging from 4.5 to 123 nM.{53038} It exhibits 69 and 44% tumor growth inhibition in an HCT116 mouse xenograft model and a K-Ras-mutant CRC patient-derived xenograft (PDX) mouse model, respectively, when administered at a dose of 40 mg/kg.
Brand:CaymanSKU:28757 - 10 mgAvailable on backorder
TP-0903 is an inhibitor of the receptor tyrosine kinase Axl (IC50 = 27 nM ).{53037} It exhibits greater than 50% inhibition of 11 kinases, including MER, TYRO3, JAK2, ALK, and Abl1, in a panel of 75 kinases at 200 nM, with IC50 values of 3 and 12.4 nM for Aurora A and B, respectively. TP-0903 decreases the phosphorylation of Akt and Axl in GAS6-stimulated, serum-starved PSN-1 pancreatic cancer cells (EC50s = 305 and 222 nM, respectively). It decreases cell viability (IC50 = 6 nM) and induces cell cycle arrest at the G2/M phase in PSN-1 cells when used at a concentration of 30 nM. TP-0903 also reduces the viability of colorectal cancer (CRC) cell lines with IC50 values ranging from 4.5 to 123 nM.{53038} It exhibits 69 and 44% tumor growth inhibition in an HCT116 mouse xenograft model and a K-Ras-mutant CRC patient-derived xenograft (PDX) mouse model, respectively, when administered at a dose of 40 mg/kg.
Brand:CaymanSKU:28757 - 25 mgAvailable on backorder
TP-0903 is an inhibitor of the receptor tyrosine kinase Axl (IC50 = 27 nM ).{53037} It exhibits greater than 50% inhibition of 11 kinases, including MER, TYRO3, JAK2, ALK, and Abl1, in a panel of 75 kinases at 200 nM, with IC50 values of 3 and 12.4 nM for Aurora A and B, respectively. TP-0903 decreases the phosphorylation of Akt and Axl in GAS6-stimulated, serum-starved PSN-1 pancreatic cancer cells (EC50s = 305 and 222 nM, respectively). It decreases cell viability (IC50 = 6 nM) and induces cell cycle arrest at the G2/M phase in PSN-1 cells when used at a concentration of 30 nM. TP-0903 also reduces the viability of colorectal cancer (CRC) cell lines with IC50 values ranging from 4.5 to 123 nM.{53038} It exhibits 69 and 44% tumor growth inhibition in an HCT116 mouse xenograft model and a K-Ras-mutant CRC patient-derived xenograft (PDX) mouse model, respectively, when administered at a dose of 40 mg/kg.
Brand:CaymanSKU:28757 - 5 mgAvailable on backorder
TP-238 is a chemical probe for the bromodomains of cat eye syndrome chromosome region, candidate 2 (CECR2) and bromodomain PHD finger transcription factor (BPTF). It has on-target biochemical activity with CECR2 when used at concentrations ranging from 10 to 30 nM and with BPTF at concentrations ranging from 100 to 350 nM. It is selective for the CECR2 and BPTF bromodomains over BRD9 (IC50 = 1.4 µM), as well as over a panel of 338 kinases at 1 µM. TP-238 binds to CECR2 and BPTF with KD values of 10 and 120 nM, respectively, in an isothermal titration calorimetry (ITC) assay and IC50 values of 30 and 350 nM, respectively, in an AlphaScreen® assay. See the Structural Genomics Consortium (SGC) website for more information.
Brand:CaymanSKU:27254 - 1 mgAvailable on backorder
TP-238 is a chemical probe for the bromodomains of cat eye syndrome chromosome region, candidate 2 (CECR2) and bromodomain PHD finger transcription factor (BPTF). It has on-target biochemical activity with CECR2 when used at concentrations ranging from 10 to 30 nM and with BPTF at concentrations ranging from 100 to 350 nM. It is selective for the CECR2 and BPTF bromodomains over BRD9 (IC50 = 1.4 µM), as well as over a panel of 338 kinases at 1 µM. TP-238 binds to CECR2 and BPTF with KD values of 10 and 120 nM, respectively, in an isothermal titration calorimetry (ITC) assay and IC50 values of 30 and 350 nM, respectively, in an AlphaScreen® assay. See the Structural Genomics Consortium (SGC) website for more information.
Brand:CaymanSKU:27254 - 10 mgAvailable on backorder
TP-238 is a chemical probe for the bromodomains of cat eye syndrome chromosome region, candidate 2 (CECR2) and bromodomain PHD finger transcription factor (BPTF). It has on-target biochemical activity with CECR2 when used at concentrations ranging from 10 to 30 nM and with BPTF at concentrations ranging from 100 to 350 nM. It is selective for the CECR2 and BPTF bromodomains over BRD9 (IC50 = 1.4 µM), as well as over a panel of 338 kinases at 1 µM. TP-238 binds to CECR2 and BPTF with KD values of 10 and 120 nM, respectively, in an isothermal titration calorimetry (ITC) assay and IC50 values of 30 and 350 nM, respectively, in an AlphaScreen® assay. See the Structural Genomics Consortium (SGC) website for more information.
Brand:CaymanSKU:27254 - 5 mgAvailable on backorder
TP-3654 is an inhibitor of Pim kinases (Kis = 5, 239, and 42 nM for Pim-1, Pim-2, and Pim-3, respectively).{45703} It inhibits 19 additional kinases, including PI3Kα, PI3Kγ, and PI3Kδ, with IC50 values of less than 300 nM. TP-3654 inhibits phosphorylation of Bad in HEK293 cells overexpressing Bad and Pim-1 (EC50 = 67 nM), as well as in UM-UC-3 cells. It reduces tumor growth in UM-UC-3 bladder carcinoma and PC3 prostate adenocarcinoma mouse xenograft models when administered at a dose of 200 mg/kg.
Brand:CaymanSKU:29571 - 10 mgAvailable on backorder
TP-3654 is an inhibitor of Pim kinases (Kis = 5, 239, and 42 nM for Pim-1, Pim-2, and Pim-3, respectively).{45703} It inhibits 19 additional kinases, including PI3Kα, PI3Kγ, and PI3Kδ, with IC50 values of less than 300 nM. TP-3654 inhibits phosphorylation of Bad in HEK293 cells overexpressing Bad and Pim-1 (EC50 = 67 nM), as well as in UM-UC-3 cells. It reduces tumor growth in UM-UC-3 bladder carcinoma and PC3 prostate adenocarcinoma mouse xenograft models when administered at a dose of 200 mg/kg.
Brand:CaymanSKU:29571 - 25 mgAvailable on backorder
TP-3654 is an inhibitor of Pim kinases (Kis = 5, 239, and 42 nM for Pim-1, Pim-2, and Pim-3, respectively).{45703} It inhibits 19 additional kinases, including PI3Kα, PI3Kγ, and PI3Kδ, with IC50 values of less than 300 nM. TP-3654 inhibits phosphorylation of Bad in HEK293 cells overexpressing Bad and Pim-1 (EC50 = 67 nM), as well as in UM-UC-3 cells. It reduces tumor growth in UM-UC-3 bladder carcinoma and PC3 prostate adenocarcinoma mouse xenograft models when administered at a dose of 200 mg/kg.
Brand:CaymanSKU:29571 - 5 mgAvailable on backorder
TP-472 is an inhibitor of bromodomain BRD9 (Kd = 33 nM; EC50 = 320 nM in a NanoBRET assay). It has >30-fold selectivity over all other bromodomain family members with the exception of the highly homologous BRD7 bromodomain (Kd = 340 nM in an isothermal titration calorimetry (ITC) assay). See the Structural Genomic Consortium (SGC) website for more information.
Brand:CaymanSKU:20030 -Available on backorder
TP-472 is an inhibitor of bromodomain BRD9 (Kd = 33 nM; EC50 = 320 nM in a NanoBRET assay). It has >30-fold selectivity over all other bromodomain family members with the exception of the highly homologous BRD7 bromodomain (Kd = 340 nM in an isothermal titration calorimetry (ITC) assay). See the Structural Genomic Consortium (SGC) website for more information.
Brand:CaymanSKU:20030 -Available on backorder
TP-4748 is a heterocyclic building block.{52779} It has been used in the synthesis of prolyl-tRNA synthase inhibitors.
Brand:CaymanSKU:31459 - 10 mgAvailable on backorder
TP-4748 is a heterocyclic building block.{52779} It has been used in the synthesis of prolyl-tRNA synthase inhibitors.
Brand:CaymanSKU:31459 - 25 mgAvailable on backorder
TP-4748 is a heterocyclic building block.{52779} It has been used in the synthesis of prolyl-tRNA synthase inhibitors.
Brand:CaymanSKU:31459 - 50 mgAvailable on backorder
Brand:CaymanSKU:24181 - 10 mgAvailable on backorder
Brand:CaymanSKU:24181 - 25 mgAvailable on backorder
Brand:CaymanSKU:24181 - 5 mgAvailable on backorder